Your browser doesn't support javascript.
loading
A rapid and sustained improvement of calcification propensity score (serum T50 ) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate.
Smerud, Knut T; Åsberg, Anders; Kile, Håkon; Pasch, Andreas; Dahle, Dag O; Bollerslev, Jens; Godang, Kristin; Hartmann, Anders.
Afiliación
  • Smerud KT; Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Åsberg A; Smerud Medical Research International AS, Oslo, Norway.
  • Kile H; Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Pasch A; The Norwegian Renal Registry, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Dahle DO; School of Pharmacy, University of Oslo, Oslo, Norway.
  • Bollerslev J; Smerud Medical Research International AS, Oslo, Norway.
  • Godang K; Calciscon AG, Bern, Switzerland.
  • Hartmann A; Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Clin Transplant ; 31(12)2017 Dec.
Article en En | MEDLINE | ID: mdl-28972673
ABSTRACT
A serum test called T50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3 weeks after transplantation) in 129 patients, at 10 weeks in 127 patients and at 1 year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T50 at 10 weeks (P = .094) or at 1 year (P = .116). Baseline T50 was a significant covariate (P < .0001) for T50 scores at 10 weeks and 1 year. In the total cohort, there was a highly significant (P < .0001) increase in T50 of 26.6% after 10 weeks and T50 remained stable after 1 year. T50 change was inversely correlated to phosphate of -0.515 (P < .0001) and to change in serum albumin (P < .03). We found that T50 increased from baseline to 10 weeks after transplantation with no further change after 1 year. Ibandronate had no effect on T50 .
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calcinosis / Trasplante de Riñón / Difosfonatos / Conservadores de la Densidad Ósea / Puntaje de Propensión / Supervivencia de Injerto / Fallo Renal Crónico Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calcinosis / Trasplante de Riñón / Difosfonatos / Conservadores de la Densidad Ósea / Puntaje de Propensión / Supervivencia de Injerto / Fallo Renal Crónico Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Año: 2017 Tipo del documento: Article